Building upon our success in identifying food pathogens in produce (fruits and vegetables), we have updated the design of the various components to be able to identify bacteria, virus, pollen and other protein-based pathogens in small specimen samples with very high sensitivity.
Currently, we have developed a solution for the quick and timely diagnosis of the SARS-CoV-2 virus, which has caused the largest pandemic in recent history.
Looking to the future, we are developing rapid anti-body tests for COVID-19 which can evaluate immunity levels in person’s who have received a vaccination. As at present, there is no reliable data to indicate how long immunity from a vaccine will last. Only periodic anti-body testing, over a period of 2-3 years will provide accurate, actionable data. Additionally, rapid tests for other medical conditions such as tests for allergens, certain cancers, infectious diseases such as dengue fever, and other mutations of the SARS virus, will be created by KAYA17. Some basic research for these tests has already been completed.
The KAYA17 Team
Sulatha Dwarakanath, PhD
CEO / Co-Founder
Su has a PhD in Molecular Biology from New York University. She has over 20 years of experience in Product Innovation, Development and Strategy. She was the Founder and Chief Scientific Officer of Nano Science Diagnostics, a Point of Care focused company.
Srinagesh Satyanarayana, PhD
CTO / Co-Founder
Sri has a PhD in Electrical Engineering from Columbia University. He has more than 25 years of experience in Analog chip design electronic systems, medical devices, and Artificial Intelligence based systems. He was the Founder and CEO of Free Electron Technology.
Camille Troup, PhD
Chief Scientific Officer
Camille received her PhD in Molecular Biology from University of California at San Francisco. She has over 25 years of experience developing and commercializing biomolecular assays and platforms.
Chief Operations Officer
Anup brings more than 20 years of experience in delivering innovative solutions to support multiple aspects of clinical trials.
VP of Business Development
VP of Business Development
Rajan co-founded Duramed Pharmaceuticals, Trinity Laboratories, and Medi Rx America. He was Managing Director at Peregrine Capital Ltd. As a practicing attorney he has represented the Governments of Indonesia and Sweden and has handled several IPOs of successful early stage enterprises.
Steve Verbinski, MD
Chief Medical Officer
Dr. Verbinski received his Bachelors from Stanford university, M.D from Duke University Medical School. He served as Nocturnist/Hospitalist at San Mateo General Hospital and at Eden Medical Center, Castro Valley CA. He is currently Full time Hospitalist and Co-director at St. Rose Hospital Hayward, CA.
Shreefal Mehta Ph.D., MBA
Chief Commercialization Officer
Shreefal has successfully brought new biotechnology and electronics hardware from lab prototypes to market. He has raised millions of dollars from venture capital, forged strategic partnerships with Fortune 500 companies and driven over $350M in licensing and sales revenues.
Kevin Seltzer, JD, CPA
Chief Financial Officer
Kevin has over 25 years of financial experience focused on planning; budgeting; forecasting; and creating efficiencies, work flows, operating leverage, scalability, and enterprise value. Kevin recently drove steady growth both organically and through acquisition as the CFO for Open Systems Health Care.
George H. Caughey, MD
Chief of Pulmonary and Critical Care Medicine, Julius and Lilian Nadel Endowed Chair, UCSF; Professor Emeritus, Medicine, UCSF.
Nancy B. Mozelsio, MD
Clinical Practice, Allergy & Asthma Medical Group of Bay Area, Pleasanton & Walnut Creek.
Founder Traction; Digital Marketing for Tech and Biotech.
Medical Device Developer & Entrepreneur Experienced medical device developer and entrepreneur with over 30 years in the industry. In 2010, Mr. Levinson co-founded Cerebrotech Medical Systems, Inc.. Previously CEO of Zeltiq Aesthetics, Inc. (Coolsculpting, ZLTQ) and VP of Thermage, Inc. (later renamed Solta Medical, SLTA). Levinson also sits on the Board of Directors of Pulse Biosciences (PLSE) and ConnectWell.
Allyson Tevrizian, MD
Clinical Practice, Allergy and Asthma Medical Group of Bay Area, Pleasanton
Peter Andreotti, MD
Dr. Andreotti has over 25 years of experience developing immunoassays including more than 10 years of contractor experience (2002-2012) developing TRF and CLIA assays for special pathogens and toxins as a DARPA PI and PI for DHS and the CDC/LRN. Dr. Andreotti was also a PM for the AF/SGR to develop a multiplex rt-PCR platform for the Epidemic Outbreak Surveillance (EOS) program in collaboration with CDC.